Metabolism Disorder TRIZ Cases

Site-specific cysteine crosslinking extends the circulatory half-life of oxyntomodulin analogs without reducing their anti-hyperglycemic potency.

Oral nutritional composition containing leucine and resveratrol reduces insulin levels, increasing adiponectin to treat equine metabolic syndrome.

Immunomodulatory compounds stimulate adipocytes to secrete leptin and adiponectin.

Maternal supplementation with enzymatic stabilized rice bran extracts increases breast milk quantity and quality to mitigate chronic infant malnutrition.

Administering a ghrelin agonist counteracts dexamethasone-induced suppression of growth hormone, restoring lean body mass and bone density.

Oral Calebin A lowers LDL and VLDL while raising HDL to address hypercholesterolemia.

A platelet-rich fraction reprograms adult mononuclear cells into insulin-producing populations without viral vectors.

A liquid formulation of long-acting insulinotropic peptide conjugate uses an albumin-free stabilizer to maintain stability.

Segmented tablet layers release magnesium ions at distinct rates through wet granulation, reducing concentration peaks and side effects.

Nell1 protein mediates angiogenesis and muscle regeneration, reducing wound healing time by up to 75 percent while improving functional recovery.

Apremilast modulates inflammatory pathways via phosphodiesterase 4 inhibition to induce weight loss.

UV-B irradiation of a mushroom slurry ruptures cell walls to boost Vitamin D2 levels while reducing processing time.

Co-polyamino acids prevent amylin fibril formation in aqueous solutions, enabling stable injectable compositions with prandial insulin.

Deleting 7DHC reducing genes in Labyrinthulea microorganisms overcomes host growth trade-offs and animal-derived safety risks.

Citrate buffer extraction isolates alpha-amylase inhibitors from Phaseolus vulgaris seeds while preserving enzymatic activity.

Metoprolol blocks beta-1 adrenoceptors to prevent tesofensine-induced heart rate increases without reducing weight loss efficacy.

Mangifera indica herbal composition reduces body weight and abdominal fat without toxic side effects.

Fermented green tea peptide composition inhibits lipid synthesis and promotes fat oxidation, resolving side effects from synthetic anti-obesity drugs.

Albumin binder covalently attached to FGF21 reduces clearance and improves oxidative stability for metabolic disorder treatment.

Novel EP3 antagonists preserve beta-cell mass by blocking apoptotic signaling, addressing progressive dysfunction in diabetes treatment.

DRP1 inhibitors reduce PCSK9 secretion to increase LDL receptor expression, lowering cholesterol without liver toxicity from statins.

Concentrated herbal oral paste delivers active ingredients through decoction and evaporation to condition the phlegm-dampness constitution.

Combining cyproheptadine with cannabidiol stimulates appetite through dual receptor pathways.

Engineered microbiome produces anti-atrophic agents to reverse muscle wasting and improve survival in cancer cachexia.

Polysorbate-free vitamin A emulsions enable flexible intravenous dosing for preterm infants using lecithin-stabilized oil-in-water systems.

Analyzing gut microbiota profiles to predict weight loss response, enabling personalized dietary interventions that resolve generic treatment inefficiency.

Saxagliptin organic acid salts prevent intramolecular cyclization into amidine impurities, enabling high-purity isolation.

Enterically coated solid dosage forms use pH-sensitive polymers to release bacterial agents in the small intestine, improving therapeutic efficacy.

Flow cytometry quantifies MAIT and iNKT cell populations to resolve inadequate prognosis accuracy in type 1 diabetes assessment.

An oil-proof coating layer on a solid statin preparation prevents omega-3 fatty acid penetration, maintaining drug stability and preventing side effects.

Modifying cyclosporin A residues creates NTCP inhibitors that treat hepatitis while reducing immunosuppression.

Segmenting full-length AARS sequences reveals resectins with extracellular signaling functions, enabling diagnostic and therapeutic applications.

Barcode-based bin analysis identifies structural variations by detecting shared sequence reads across genomic regions.

Pegylated arginase reduces serum arginine and GAA levels, bypassing restrictive dietary compliance challenges in GAMT deficiency treatment.

Dual-function conjugated therapeutic agent extends metabolic control duration by combining GLP-1 receptor activation with GIPR blockade.

Farnesol targets PARIS farnesylation to increase PGC-1α expression, resolving the gap between unknown mechanisms and improved muscle metabolism.

Segmented assay systems identify biased agonists that improve insulin sensitivity and lower blood glucose levels.

Segmenting multiple biomarker assessments across iPSC-derived endothelial cells improves diagnostic precision while maintaining operational simplicity.

Extending asfotase alfa injection intervals reduces patient burden while maintaining bone mineralization through periodic action and parameter changes.

Modified exendin-4 peptides enhance solubility and stability through specific amino acid substitutions.

Combining finerenone with an SGLT2 inhibitor targets distinct renal pathways to drive over-additive sodium excretion.

Milk protein isolate powder combines with resistant dextrins and Tara gum to create a high-viscosity nutritional composition.

Covalent insulin receptor partial agonist dimers provide sustained glucose lowering through submaximal receptor activation.

GC-C receptor agonists reduce fluid retention and improve gastrointestinal motility in heart failure treatment.

Linagliptin increases endogenous GLP-1 levels to reduce caloric intake, addressing obesity without complex behavioral interventions.

Lyophilized solid dosage forms preserve bacterial viability and improve bioavailability while maintaining formulation stability during manufacturing.